“Cuba is about to launch an anticovid vaccine that is administered through the nose,” headlines newspaper El Mundo, which highlights the progress in clinical trials of the new vaccine candidate from the Center for Genetic Engineering and Biotechnology (CIGB).

The aforementioned newspaper reproduced the “tweet” of the CIGB on the positive results that support the use of Mambisa in the application of booster doses.

Unlike injectables, nasal vaccines increase local immunogenicity in the mucous membranes, the site of entry of the pathogen, which allows it to be neutralized early.

The Cuban health authorities are deploying an immunization campaign with the national Sovereign 02, Sovereign Plus and Abdala vaccines, and to date nearly 10 million citizens on the island have completed their vaccination schedule.

ef/mem/cmv